Arjuna Capital Purchases 46,621 Shares of GSK plc (NYSE:GSK)

Arjuna Capital increased its position in shares of GSK plc (NYSE:GSK - Free Report) by 144.3% during the third quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 78,934 shares of the pharmaceutical company's stock after buying an additional 46,621 shares during the period. Arjuna Capital's holdings in GSK were worth $3,227,000 as of its most recent filing with the SEC.

A number of other hedge funds have also recently added to or reduced their stakes in GSK. SG Americas Securities LLC lifted its stake in shares of GSK by 448.7% in the first quarter. SG Americas Securities LLC now owns 17,690 shares of the pharmaceutical company's stock worth $758,000 after buying an additional 14,466 shares in the last quarter. Thoroughbred Financial Services LLC purchased a new position in GSK in the first quarter worth approximately $277,000. US Bancorp DE lifted its position in shares of GSK by 54.6% during the 1st quarter. US Bancorp DE now owns 181,647 shares of the pharmaceutical company's stock worth $7,787,000 after buying an additional 64,144 shares during the last quarter. Dearborn Partners LLC lifted its position in shares of GSK by 21.5% during the 1st quarter. Dearborn Partners LLC now owns 12,992 shares of the pharmaceutical company's stock worth $557,000 after buying an additional 2,300 shares during the last quarter. Finally, Ledyard National Bank lifted its position in shares of GSK by 97.5% during the 1st quarter. Ledyard National Bank now owns 13,366 shares of the pharmaceutical company's stock worth $573,000 after buying an additional 6,597 shares during the last quarter. 15.74% of the stock is owned by hedge funds and other institutional investors.

GSK Price Performance

GSK stock traded down $0.41 during trading on Wednesday, hitting $35.11. The company had a trading volume of 7,277,722 shares, compared to its average volume of 4,030,205. The company has a current ratio of 0.81, a quick ratio of 0.53 and a debt-to-equity ratio of 0.98. The business has a 50 day moving average of $39.65 and a 200 day moving average of $40.84. GSK plc has a fifty-two week low of $34.29 and a fifty-two week high of $45.92. The firm has a market capitalization of $72.77 billion, a price-to-earnings ratio of 22.80, a P/E/G ratio of 1.36 and a beta of 0.66.

GSK Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Thursday, January 9th. Shareholders of record on Friday, November 15th will be paid a dividend of $0.3928 per share. This represents a $1.57 annualized dividend and a yield of 4.48%. The ex-dividend date is Friday, November 15th. This is a boost from GSK's previous quarterly dividend of $0.38. GSK's payout ratio is 98.70%.

Insider Buying and Selling at GSK

In other news, major shareholder Plc Gsk purchased 2,791,930 shares of the stock in a transaction that occurred on Friday, September 27th. The stock was acquired at an average price of $8.00 per share, with a total value of $22,335,440.00. Following the purchase, the insider now owns 16,775,691 shares in the company, valued at $134,205,528. This represents a 0.00 % increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Company insiders own 10.00% of the company's stock.

Analyst Ratings Changes

GSK has been the topic of several recent research reports. Argus raised shares of GSK to a "strong-buy" rating in a research note on Wednesday, August 7th. Barclays raised shares of GSK to a "hold" rating in a research note on Tuesday, August 27th. Jefferies Financial Group lowered shares of GSK from a "buy" rating to a "hold" rating and decreased their price objective for the stock from $53.00 to $39.50 in a research report on Tuesday. Finally, Guggenheim lowered shares of GSK from a "buy" rating to a "neutral" rating in a report on Thursday, October 31st. Six research analysts have rated the stock with a hold rating and three have given a strong buy rating to the stock. According to MarketBeat, the stock has an average rating of "Moderate Buy" and an average target price of $43.25.

GSK Company Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.